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Summary.-We have studied granulocyte-macrophage progenitor cells (GM-CFC)
in serial bone marrow aspirates from 43 children who had been treated for acute
lymphoblastic leukaemia (ALL). All patients were in full remission, not receiving
anti-leukaemic therapy and 42 out of the 43 had normal peripheral blood counts.
Thirty-seven patients have received standard amounts of chemotherapy and 6 have
received additional therapy for relapses occurring in the first treatment-free interval.
In the former group estimation of GM-CFC incidence did not provide evidence of
long-term residual bone-marrow damage. In the latter, however, the mean incidence
of GM-CFC was significantly reduced. This reduction was also apparent when the
incidence of GM-CFC was related to the incidence of non-haemopoietic progenitor
cells within the marrow (CFU-F).
WITH INCREASING USE of more effective
chemotherapy the long-term hazards of
cytotoxic drugs are becoming apparent.
Functional damage to pulmonary tissue
(Sostmann et al., 1977), cardiac tissue
(Bonnadonna & Monfardini, 1969), cere-
bral (McIntosh & Aspons, 1973), endo-
crine and gonadal tissue (Shalet, 1980) is
well recognized. The bone marrowis one of
the most sensitive organs to immediate
damage by chemotherapeutic agents, but
due to the rapid cell turnover and the
extensive capacity of the stem cells to
repopulate the marrow, relatively little
attention has been paid to long-term
functional damage in this organ. It is
possible that normal haematological re-
covery, as defined by a normal peripheral
blood count, may occur in the presence of
occult bone-marrow damage. In mice,
Morley & Blake (1974) have shown that
repeated exposure to busulphan may
result in apparently haematologically nor-
mal mice which have a high risk of late
aplasia developing after a time interval
equivalent to one-third ofthe normal life-
span of the mouse. Investigation of these
mice shows reduction in the numbers of
multipotential cells (CFU-S) as demon-
stratedby the spleen colony-forming assay
(Till & McCulloch, 1961) a long time before
the development ofaplasia.
Quantitation of GM-CFC in patients
after cytotoxic drug therapy has been
performed with inconclusive results. In
adult patients with lymphomas Bull et al.
(1975) reported no reduction in incidence
of GM-CFC in 5 patients treated with
MOPP or intervals of 1S-6 years after
therapy, but in children Hartmann et al.
(1979) have shown areduction in the mean
numbers ofGM-CFC in 18 children treated
for non-Hodgkin's lymphoma, between 1
and 19 months following chemotherapy. A
study of 30 children treated for ALL has
been reported (Inoue et al., 1980) in which
no alteration in GM-CFC incidence was
detected attimes between 6monthsand31
years following chemotherapy. However,
the methodusedincludedtheseparation ofBONE MARROW DAMAGE IN ALL
GM-CFC-enriched marrow, which may
have masked an overall reduction in
incidence ofGM-CFC.
Quantitative work on human bone-
marrow progenitors is handicapped by the
problems ofrelating incidence of GM-CFC
in aspirated bone-marrow samples to total
body GM-CFC, and hence there is a need
for caution in the interpretation of
results. In addition, GM-CFC level as an
index of damage is insensitive. Testa and
Hendry (personal communication) have
shown that, in the mouse, amplification
within the committed progenitor compart-
ment may result in a modest decrease in
GM-CFC compared to earlier progenitor
cells (CFU-S). Itis thus likelythatreduced
incidence of GM-CFC will detect only
relatively severe damage to the bone
marrow.
Because children treated for acute
lymphoblastic leukaemiarepresentapopu-
lation of patients who having received
anti-cancer chemotherapy have a long life
expectancy, it was important to investi-
gate bone marrow function in vitro in
these patients to assess the degree of
damage and whether it recovers with time.
Long-term impairment of bone-marrow
function may result in impaired tolerance
of future chemotherapy or in further
marrow pathology-e.g. late-developing
aplasia or second haematological
neoplasms.
In this preliminary study we use
imbalance ofhaemopoietic progenitor cells
(GM-CFC) and non-haemopoietic cells
within the marrow-colony-forming units
fibroblastic (CFU-F) as confirmation of
genuine reduction of GM-CFC in the bone
marrow of a minority of patients. In
addition we have followed patients for up
to 3- years after therapy to assess the
tendency to recover in those whom we
judge to have post-chemotherapy damage.
PATIENTS AND METHODS
From January 1979 to December 1981 all
patients treated at the Royal Manchester
Children's Hospital for acute lymphoblastic
leukaemia in whom chemotherapy was termi-
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nated and who remained in unmaintained
remission had bone-marrow aspirates assayed
for GM-CFC. The patients studied were
unselected with respect to previous anti-ALL
protocols, the majority having been treated
by one of the following schedules: Memphis,
V, Memphis, VIII, UKALL II, UKALL V.
Patients were divided into 2 groups
according to whether they had received
standard amounts of chemotherapy, consist-
ing of induction plus between 24 and 36
months' maintenance (Group I, 37 patients);
or whether they had received additional
chemotherapy for relapses which had occur-
red during the first treatment-free period
(Group II, 6 patients). Two of the latter
received an extra 18 months' chemotherapy
plus local radiotherapy for testicular relapses
occurring 4 and 6 months aftertreatment; the
4 remaining patients received 3 years chemo-
therapy for haematological relapse. Patients
who relapsed while off therapy were treated
individually with 6MP, methotrexate, cyclo-
phosphamide, vincristine and prednisolone,
sometimes in combination with cytosine
arabinoside and/or adriamycin. This group of
patients was necessarily smaller than Group I
as few patients were available for entry into
this group.
Control marrow was from surgically resec-
ted ribs from haematologically normal adults,
and also from normal children undergoing
cold orthopaedic surgery, whose parents had
given informed consent for bone-marrow
aspiration. (Ethical-Committee approval was
granted by Salford Area Health Authority.)
Control and test marrows were aspirated from
the iliac crest. All samples were immediately
suspended in heparinized tissue-culture
medium. A single-cell suspension of marrow
waswashedinMcCoy'stissue-culture medium
and diluted to a nucleated cell concentration
of 1 x 105/ml in McCoy's medium (in which
the L-glutamine was increased by 0-2mM and
the L-asparagine by 0-15mM), 15% foetal calf
serum (Sera Labs) or donor calf serum (Sera
Labs) and 0 3% agar.
Colony-stimulating activity (CSA) from 2
sources was used: (a) initially peripheral
blood feeder layers from normal donors,
according to the method of Pike & Robinson
(1970); in each experiment, triplicate plates
from each of2 or 3 different feederlayers were
used according to the recommendations for
the standardization of bone-marrow culture
(Moore et at., 1977); (b) for the major part
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TABLE I.-Haemoglobin
Group I
Group II
Normal range
levels, neutrophils and platelet
of therapy*
Hb g/dl
+1 s.d.
13-9+1-00
13-2+1-6
13 -2+ 1-Ot
Neutrophil
count (x 109/1)
(mean, 95% range)
4-0
1 -8-11-0
3 -6
2-2-7-7
3-65
1-83-7-25:
counts 1 year after cessation
Platelet
count (x 109/1)
(mean, 95% range)
201
138-300
154
29-260
150-400
* Where 1-year follow-ups are not available the nearest point has been
taken.
t 10 year-old children (Lascari, 1973)
: Orfanakis et al., 1970.
CSA was obtained from PHA-stimulated
leucocyte-conditioned medium (PHA-LCM)
using blood from haemochromatic patients
(Aye et al., 1974). Results from feeder layer
sources of CSA were considered valid only if
control marrows had GM-CFC assays within
the normal range.
The cultures were incubated for 8 days at
370Cinahumidifiedatmosphere of5% C02in
air. Colonies of >50 cells were scored using an
inverted microscope. Statistical analysis was
performed on the logarithmic means of both
groups vs each control group using Duncan's
test.
In addition, marrows were assayed on 16
occasions for cells which gave rise to colonies
of fibroblast-like cells (CFU-F) and believed
to be a part of the haemopoietic microen-
vironment (Friedenstein et al., 1974). The
method used was similar to that of Castro-
Malaspina et at. (1980). Bone-marrow (5 x 105
cells) was incubated in flat-bottomed flasks
(Sterilin) in cx-medium (Gibco) containing
15% pre-testedfoetal calfserum in5% C02 in
air. After 4 days non-adherent cells were
removed and fresh medium replaced. The
cultures were terminated after 11 days,
washed with PBS and stained with May-
Grunwald Giemsa stain.
results reported are on bone-marrow
aspirates in which the fragments are of
normal cellularity and have a normal
myeoloid:erythroid ratio.
The incidence of GM-GFC/105 bone-
marrow cells followed a non-Gaussian
distribution. The median on assaying
102
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RESULTS
The haematological findings ofGroups I
and II are shown in Table 1. The only
consistent abnormality was one patient in
Group II who was persistently thrombo-
cytopenic (27-70 x 109/1). Thispatient was
noted to have hypocellular marrow frag-
ments on repeated examination. All other
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FIG. 1.-GM-CFC in 37 Group I, 6 Group II
patients and 19 controls. In the patient
groups each point may represent the mean
of up to 5 determinations. Group II
patientsaredesignated bythe samesymbols
as in Fig. 2.
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TABLE II.-Comparison of logarithmic means between paediatric controls and standard
treated and extra chemotherapy (C/T)-treated patients
Di
Comparison
Paediatric controls
extra C/T group
Paediatric control
standard C/T group
Standard C/T group
extra C/T group
Y~~~~~~~
A
0 10 20 30 40
Months since cessation of c/t
lifference in
log levels
1*646
0 644
1*004
Least significant
range at 1% level
1*18
0-89
0*83
TABLE III.-GM-CFC/105 nucleated bone-
marrow cells in patients who have
suffered haematological relapses while off
therapy
0X
3 Al
FIG. 2.-GM-CFC/105 bone-marrow cells in
time for 6 patients of Group II.
normal adult bone marrow was 24 (range
14-100). The median of 19 paediatric
controls was 20 (range 7-105).
The results of the patients with stand-
ard amounts of chemotherapy (97 studies
on 37 patients) show a slightly wider
distribution than the controls, but there is
no significant difference between this
group (median 24 GM-CFC/105 cells) and
either control group (Fig. 1). We con-
sidered the possibility that, within Group
I, patients with a lower mean incidence of
Patient GM-CFC/105
JG 17
SH 99
29
JK 24
ST 21*5
Months before diagnosis
or relapse
2
6
3
8
6
GM-CFC have been assayed earlier in the
treatment-free period than those with a
higher incidence, but found this was not
the case. The group of 6 patients who
received additional chemotherapy differed
as a group both from normal controls and
from the standard therapy group (Table
II). In our laboratory 90% of normal
paediatric bone marrow have GM-CFC in
the range 10-102. Group II patients had
values within this range on the 5-6
TABLE IV.-CFUF/106 nucleated bone-
marrow cells in 11 controls, 15 Group I,
and 3 Group IIpatients
Controls Group I Group II
32 10 41
32 28 61
32 31 62
37 34
52 50
60 66
61 67
66 74
102 84
102 91
130 98
130
137
150
160
Median 60 74 61
Range (32-130) (10-160)
100
80
U-
10
2 60
6
z
4C
2C
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TABLE V.-Ratio of incidence CFU* GMM-
CFCt in 6 paediatric controls and 12
patients
Control
8:1
1:3
5:1
2-5:1
2:1
2:1
Group I
8:1
1*5:1
6:1
3:1
16:1
1*5:1
6 5:1
14:1
1:1
Group II
31:1
>41:1
>61:1
* CFUF/106 nucleated bone-marrow cells.
tGM-CFC/105 nucleated bone-marrow cells.
occasions on which it was tested. The
remaining 4 patients appeared to show
persistently lower values for up to 40
months after cessation oftherapy (Fig. 2).
Four patients in Group I relapsed
during the study. All showed normal
incidence of GM-CFC at time intervals up
to 2 months before the diagnosis ofrelapse
(Table III).
The analysis of the sequential data in
each group showed no significant trend
over time.
The values for CFU-F are shown in
Table IV. There was no difference between
the control and patient groups in the
experiments performed to date. When the
incidence of GM-CFC to CFU-F is com-
pared, Group II patients obviously differ
from normals. Group I patients are
intermediate between controls and Group
II.
DISCUSSION
We have shown that in a small group of
patients who have received anti-leukaemic
therapy for an unusually long period there
is a tendency toward a low incidence of
GM-CFC. In most patients within this
group this seems to represent a new low
plateau, and is therefore analogous to the
results obtained in mice following radio-
therapy (Testa, 1979). However, in one
patient treated with chemotherapy for
testicular disease over an additional 18-
month period there was an apparent
increase in GM-CFC incidence, possibly
representing recovery.
The relationship of incidence of GM-
CFC to total body GM-CFC is variable
depending on (i) the volume ofperipheral-
blood contaminant (Gordon & Douglas,
1977), (ii) the degree of post-progenitor-
cell amplification in the marrow, (iii) M:E
ratio, (iv) marrow cellularity, (v) volume
of functioning bone marrow. Attempts
have been made to remove some of these
sources of error by expressing the results
as GM-CFC/105 metamyelocytes (Parmen-
tier et al., 1978) or per ml of marrow
(Coiffer et at., 1980). We have shown
(Table V) that the low incidence of GM-
CFC is confirmed when they are compared
to non-haemopoietic cells within the
marrow (CFU-F).
In 2 out of 9 Group I patients high
normal CFU-F and low normal GM-CFC
incidence in the marrow may be a more
sensitive indication of residual damage, a
possibility which merits further investiga-
tion.
The low incidence ofGM-CFC expressed
in Group II patients may be due to the
increased amount of chemotherapy or to
the introduction of new drugs, especially
alkylating agents, into the treatment of
relapsed patients. In this context it is
interesting to note that those patients
receiving cyclophosphamide as part of
their maintenance chemotherapy did not
differ from other Group I patients with
respect to GM-CFC incidence.
We suggest, therefore, that residual
damage to bone marrow (as shown by
reduced GM-CFC incidence) may occur
after chemotherapy; that this coexists
with normal peripheral blood counts, and
may show no tendency to recover during
moderate-term follow-up.
The mechanism of the damage is not
fully understood. It may be due either to
reduced self-renewal capacity of the stem
cells or to a secondary effect on regulatory
cells within the haemopoietic micro-
environment (Trentin, 1971). Either
mechanism may lead to further bone-
marrow pathology, and we are investiga-
ting both possibilities using in vitro
techniques.
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